CRP and metabolic syndrome: The implant does not exert a negative effect on cardiovascular risk factors (such as C-reactive protein (CRP), cholesterol/HDL ratio) [71,72] nor on carbohydrate metabolism [73,74,75,76]; furthermore, its use is related to lower risk of insulin resistance and dyslipidemia [76].